Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omacetaxine + decitabine
- Development stage
- Discontinued
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
Omacetaxine + decitabine is an investigational combination therapy being evaluated for the treatment of older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Omacetaxine mepesuccinate is a semisynthetic plant alkaloid derived from homoharringtonine that acts as a protein synthesis inhibitor by binding to the ribosomal A-site, thereby downregulating proteins involved in cell survival and proliferation, such as MCL-1. Decitabine is a hypomethylating agent that incorporates into DNA and inhibits DNA methyltransferase, leading to the reactivation of silenced tumor suppressor genes. This combination, primarily investigated by the M.D. Anderson Cancer Center, aims to synergistically target malignant stem cells and provide a lower-intensity treatment option for patients who may not tolerate standard intensive chemotherapy.
- Other names
- omacetaxine mepesuccinate and decitabineOM + DAC
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)Ribosome
Beyond the preview
Go deeper on omacetaxine + decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omacetaxine + decitabine.